Opinions Stockchase Insights
Intellia TherapeuticsNTLARISKYMar 29, 2024
Stockchase InsightsUnknown
$27.51
Stock price when the opinion was issued
$12.20
As of Jun 10, 2026. Market Open.
biotechnology
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
TOP PICK
Biotech is an exciting area to be looking at. It is higher growth but higher risk - along with higher reward. Biotech has under-performed for the past two years. Intellia has used crisper technology to target mutated genes dealing with autoimmune and rare diseases - and try to cure them. They are at third stage trials this year. It has $2 billion cash which is good for two years of R&D. Management is good. Buy 25 Hold 6 Sell 0
(Analysts’ price target is $69.96)
Rob LauzonOwned
biotechnology
NTLA has $912.2M in total cash and short term investments. Cash and equivalents is $226.7M while $685.5M is in short term investments. Insider ownership is 9.39%. NTLA is expected to be highly unprofitable over the next three years, but revenue is expected grow at 40% this year, then flat in 2025. We think it is a very speculative play and it is also highly unprofitable and burning through cash at a high rate. Share price appreciation will be reliant on bringing NTLA-2001 to market.
Unlock Premium - Try 5i Free